Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human-derived mesenchymal stem cell conditioned medium for allergic diseases
jRCT1051240236Recruiting
- Sponsor
- Kawagoe Chuo Clinic
- Start
- Sep 2023
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of human-derived mesenchymal stem cell conditioned medium in allergy, allergic rhinitis (AR) and atopic dermatitis (AD), sponsored by Kawagoe Chuo Clinic. Primary endpoint: Improvement of subjective symptoms. Started Sep 2023; status: recruiting.
02
Drugs
human-derived mesenchymal stem cell conditioned medium
03
Conditions
allergyallergic rhinitis (AR)atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT1051240236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051240236.